By Jon "DRJ" Najarian, co-founder of OptionMonsterNEW YORK -- The bulls were all over Keryx Biopharmaceuticals ( KERX) and AEterna Zentaris ( AEZS) Monday amid optimism about their Perifosine drug. Seeking Alpha said Friday that the market hadn't realized the potential for the cancer treatment, and both stocks began the week with a bang. In the case of Keryx, someone apparently liked the news enough to sell 6,500 March 4 puts. Those were essentially insurance contracts on the stock price, so selling them represented a vote of confidence. Traders also bought calls at the March 5, 4, and 3 strikes looking for upside, according to OptionMonster's real-time tracking systems. Those calls lock in the price they need to pay to purchase the shares. Keryx closed the session up 33.51% to $4.94. More than 51,000 options traded in the session, compared with a daily average of about 3,000. AEterna Zentaris also rallied 22% to $2.14 but doesn't trade any options. Najarian owns KERX call spreads.